Reg. name: Vyxeos®
CPX-351 is a liposomal formulation of daunorubicin plus cytarabine co-encapsulated at a molar ratio of 1:5 and it is designed to deliver synergistic drug ratios to leukemia cells.
- Gordon M.J. et al. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leuk Res. Epub 2016 Dec 12;53:39-49. DOI: 10.1016/j.leukres.2016.12.002.
VYXEOS® is indicated for the treatment of adults with newly-diagnosed Therapy-related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC)
Reg. name: Dacogen
Class: Hypomethylating agent
It has been demonstrated that decitabine (Dacogen®) can cause DNA demethylation by inactivation of DNA Methyltransferase-1 (DNMT-1), the enzyme responsible for methylation of the DNA. The inhibition of this enzyme leads to in-gene promoter hypomethylation that can result in reactivation of tumour suppressor genes, inducing cellular differentiation or cellular senescence followed by programmed cell death.
- Dacogen® Summary of Product Characteristics. https://www.medicines.org.uk/emc/medicine/27127. [Accessed January 2017].
DACOGEN® is indicated for the treatment of adult patients with newly diagnosed de novo or secondary Acute Myeloid Leukemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy